Immunoregulation by capsular components of Cryptococcus neoformans

Medical Mycology

Volumn 38, Issue 6, 2000, Pages 407-417

  Vecchiarelli, A ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Cryptococcus neoformans; Galactoxylomannan; Glucuronoxylomannan; Mannoprotein

Indexed keywords

ANTIBODY; COMPLEMENT; CYTOKINE; GALACTOXYLOMANNAN; GAMMA INTERFERON; GLUCURONOXYLOMANNAN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MANNOPROTEIN; POLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DELAYED HYPERSENSITIVITY; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOREGULATION; LEUKOCYTE MIGRATION; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; POLYMORPHONUCLEAR CELL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRULENCE;

CRYPTOCOCCUS NEOFORMANS; FILOBASIDIELLA NEOFORMANS;

EID: 0034521326     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/714030973     Document Type: Review

References (139)

1. Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City, din Infect Dis 1994; 19: 1029-1033.
2. John GT, Mathew M, Snehalatha E, et al. Cryptococcosis in renal allograft recipients. Transplantation 1994; 58: 855-856.
3. Goldstein E, Rambo ON. Cryptococcal infection following steroid therapy. Ann Intern Med 1962; 56: 114-120.
4. Kwon-Chung KJ, Bennett JE. Epidemiologie differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol 1984; 120: 123-130.
5. Ruiz A, Fromtling RA, Bulmer GS. Distribution of Cryptococcus neoformans in a natural site. Infect Immun 1981; 31: 560-563.
6. Rodrigues ML, Alviano CS, Travassos LR. Pathogenicity of Cryptococcus neoformans'. virulence factors and immunological mechanism. Microbes Infect 1999; 1: 293-301.
7. Granger DL, Perfect JR, Durack DT. Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J din Invest 1985; 76: 508-516.
8. Jacobson ES, Compton GM. Discordant regulation of phenoloxidase and capsular polysaccharide in Cryptococcus neoformans. J Med Vet Mycol 1996; 34: 289-291.
9. Vartivarian SE, Anaissie EJ, Cowart RE. Regulation of cryptococcal capsular polysaccharide by iron. J Infect Dis 1993; 167: 186-190.
10. Fries BC, Goldman DL, Cherniak R, Ju R, Casadevall A. Phenotypic switching in Cryptococcus neoformans results in change in cellular morphology and glucuronoxylomannan structure. Infect Immun 1999; 67: 6076-6083.
11. Sakaguchi N, Baba T, Fukuzawa M, Ohno S. Ultrastructural study of Cryptococcus neoformans by quick-freezing and deepetching method. Mycopathologia 1993; 121: 133-141.
12. Takeo K, Uesaka I, Uehira K, Nishiura M. Fine structure of Cryptococcus neoformans grown in vivo as observed by freezeetching. J Bacterial 1973; 113: 1449-1454.
13. Vartivarian SE, Reyes GH, Jacobson ES, et al. Localization of mannoprotein in Cryptococcus neoformans. J Bacterial 1989; 171: 6850-6852.
14. Kozel TR. Non-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide. Infect Immun 1977; 16: 99-106.
15. Kozel TR, Gotschlich E. The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol 1982; 129: 1675-1680.
16. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med 1974; 80: 176-181.
17. Goldman DL, Lee SC, Casadevall A. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun 1995; 63: 3448-3453.
18. Gadebush HH. Active immunization against Cryptococcus neoformans. J Infect Dis 1958; 102: 219-226.
19. Gordon MA, Casadevall A. Serum therapy of cryptococcal meningitis. Clin Infect Dis 1995; 21: 1477-1479.
20. Cherniak R, Sundstrom JB. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect Immun 1994; 62: 1507-1512.
21. Reiss E, Cherniak R, Eby E, Kaufman L. Enzyme immunoassay detection of IgM to galactoxylomannan of Cryptococcus neoformans. Diagn Immunol 1984; 2: 109-115.
22. James PD, Cherniak R. Galactoxylomannans of Cryptococcus neoformans. Infect Immun 1992; 60: 1084-1088.
23. Turner SH, Cherniak R, Reiss E. Fractionation and characterization of galactoxylomannan from Cryptococcus neoformans. Carbohydr Res 1984; 125: 343-349.
24. Cherniak R, Sundstrom JB. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect Immun 1994; 62: 1507-1512.
25. Mody CH, Sims KL, Wood CJ, et al. Proteins in the cell wall and membrane of Cryptococcus neoformans stimulate lymphocytes from both adults and fetal cord blood to proliferate. Infect Immun 1996; 64: 4811-4819.
26. Mody CH, Wood CJ, Syme RM, Spurrel JC. The cell wall and membrane of Cryptococcus neoformans possess a mitogen for human T lymphocytes. Infect Immun 1999; 67: 936-941.
27. Reiss E, White EH, Cherniak R, Dix JE. Ultrastructure of acapsular mutant Cryptococcus neoformans Cap67 and monosaccharide composition of cell extracts. Mycopathologia 1986; 93: 45-54.
28. Hamilton AJ, Bartholomew MA, Figueroa J, Fenelon LE, Hay RJ. Production of species-specific murine monoclonal antibodies against Cryptococcus neoformans which recognize a noncapsular exoantigen. J Clin Microb 1991; 29: 980-984.
29. Hamilton AJ, Jeavons L, Hobby P, Hay RJ. A 34- to 38-kilodalton Cryptococcus neoformans glycoprotein produced as an exoantigen bearing a glycosylated species-specific epitope. Infect Immun 1992; 60: 143-149.
30. Hamilton AJ, Goodley J. Purification of the 115-kilodlaton exoantigen of Cryptococcus neoformans and its recognition by immune sera. J Clin Microbiol 1993; 31: 335-339.
31. Kozel TR, Wilson MA, Murphy JW. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect Immun 1991; 59: 3101 3110.
32. Keller RG, Pfrommer GS, Kozel TR. Occurrences, specificities, and functions of ubiquitous antibodies in human serum that are reactive with the Cryptococcus neoformans cell wall. Infect Immun 1994; 62: 215-220.
33. Houpt DC, Pfrommer GST, Young BJ, Larson TA, Kozel TR. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect Immun 1994; 62: 3857-3864.
34. Kozel TR, Tabuni A, Young BJ, Levitz SM. Influence of opsonization conditions on C3 deposition and phagocyte binding of large- and small-capsule Cryptococcus neoformans cells. Infect Immun 1996; 64: 2336-2338.
35. Laxalt KA, Kozel TR. Chemotoxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans. Infect Immun 1979; 26: 435-440.
36. Davies SF, Clifford DP, Hoidal JR, Repine JE. Opsonic requirements for the uptake of Cryptococcus neoformans by human polymorphonuclear leukocytes and monocytes. J Infect Dis 1982; 145: 870-874.
37. Diamond RD, May JE, Kane MC, Frank MM, Bennett JE. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol 1974; 112: 2260-2270.
38. Kozel TR, Highison B, Stratton CJ. Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils. Infect Immun 1984; 43: 574-579.
39. Levitz SM, Tabuni A. Binding of Cryptococcus neoformans by human cultured macrophages. Requirement for multiple complement receptors and actin. J Clin Invest 1991; 87: 528-535.
40. Cross CE, Collins HL, Bancroft GJ. CR3-dependent phagocytosis by murine macrophages: different cytokines regulate ingestion of a defined CR3 ligand and complement-opsonized Cryptococcus neoformans. Immunology 1997; 91: 289-296.
41. Ikeda R, Shinoda T, Kagaya K, Fukazawa Y. Role of serum factors in the phagocytosis of weakly or heavily encapsulated Cryptococcus neoformans strains by guinea pig blood leukocytes. Microbiol Immunol 1984; 28: 51-61.
42. Kozel TR, Pfrommer GST, Guerlain AS, Highison BA, Highison GJ. Strain variation in phagocytosis of Cryptococcus neoformans dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragment of C3. Infect Immun 1988; 56: 2794-2800.
43. Lovchik JA, Lipscomb MF. Role for C5 and neutrophils in the pulmonary intravascular clearance of circulating Cryptococcus neoformans. Am J Respir Cell Mol Biol 1993; 9: 617627.
44. Rhodes JC. Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. J Med Vet Mycol 1993; 23: 225-234.
45. Rhodes JC, Wicker LS, Urba W. Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect Immun 1980; 29: 494-499.
46. Casadevall A, Perfect JR. Cryptococcus neoformans. Washington: ASM Press, 1998.
47. Devi SJ, Schneerson R, Egan W, et al. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun 1991; 59: 3700-3707.
48. Casadevall A, Mukherjee J, Devi SJ, Schneerson R, Robbins JB, Scharff MD. Antibodies elicited by a Cryptococcus neoformotu-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis 1992; 165: 1086-1093.
49. Gadebusch HH. Active immunization against Cryptococcus neoformans. J Infect Dis 1958; 102: 219-226.
50. Murphy JW, Cozad GC. Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun 1972; 5: 896901.
51. Dromer F, Yeni P, Charreire J. Genetic control of the humoral response to cryptococcal capsular polysaccharide in mice. Immunogenetics 1988; 28: 417-424.
52. Sundstrom JB, Cherniak R. The glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigen. Infect Immun 1992; 60: 4080-4087.
53. Breen JF, Lee 1C, Vogel FR, Friedman H. Cryptococcal capsular polysaccharide-induced modulation of murine immune responses. Infect Immun 1982; 36: 47-51.
54. Perfect JR, Lang SD, Durack DT. Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol 1980; 101: 177-194.
55. Gadebusch HH. Passive immunization against Cryptococcus neoformans. Proc Soc Exp Biol Med 1958; 98: 611-614.
56. Graybill JR, Hague M, Drutz DJ. Passive immunization in murine cryptococcosis. Sabouraudia 1981; 19: 237-244.
57. Gordon MA, Casadevall A. Serum therapy for cryptococcal meningitis. Clin Infect Dis 1995; 21: 1477-1479.
58. Dromer F, Perronne C, Barge J, Vilde JL, Yeni P. Role of IgG and complement component C5 in the initial course of experimental cryptococcosis. Clin Exp Immunol 1989; 78: 412417.
59. Mukherjee J, Scharff MD, Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Im mun 1992; 60: 4534-4541.
60. Dromer F, Charreire J, Contrepois A, Carbon C, Yeni P. Protection of mice against experimental cryptococcosis by anü-Cryptococcus neoformans monoclonal antibody. Infect Immun 1987; 55: 749-752.
61. Feldmesser M, Casadevall A. Effect of serum IgGl against murine pulmonary infection with Cryptococcus neoformans. J Immunol 1997; 158: 790-799.
62. Mukherjee J, Casadevall A, Scharff MD. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med 1993; 177: 1105-1116.
63. Mukherjee J, Pirofski LA, Scharff MD, Casadevall A. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sei USA 1993; 90: 3636-3640.
64. Mukherjee J, Scharff MD, Casadevall A. Cryptococcus neoformans infection can elicit protective antibodies in mice. Can J Microbiol 1994; 40: 888-892.
65. Mukherjee S, Lee S, Mukherjee J, Scharff MD, Casadevall A. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun 1994; 62: 1079-1088.
66. Sanford JE, Lupan DM, Schlageter AM, Kozel TR. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun 1990; 58: 19191923.
67. Yuan R, Casadevall A, Spira G, Scharff MD. Isotype switching from IgG3 to IgGl converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol 1995; 154: 1810-1816.
68. Dromer F, Charreire J. Improved amphotericin B activity by a monoclonal anû-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J Infect Dis 1991; 163: 1114-1120.
69. Gordon MA, Lapa E. Serum protein enhancement of antibiotic therapy in cryptococcosis. J Infect Dis 1964; 114: 373-378.
70. Mukherjee J, Zuckier LS, Scharff MD, Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother 1994: 38: SSO587.
71. Dromer F, Salamero J, Contrepois A, Carbon C, Yeni P. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect Immun 1987; 55: 742-748.
72. Gupta S, Ellis M, Cesario T, Ruhling M, Vayuvegula B. Disseminated cryptococcal infection in a patient with hypogammaglobulinemia and normal T-cell function. Am J Med 1987; 82: 129-131.
73. Williamson PR, Bennett JE, Polis MA, Robbins JB, Schneerson R. Immunogenicity and safety of a conjugate glucuronoxylomannan-tetanus conjugate vaccine in volunteers. Clin Infect Dis 1993; 17: 540.
74. Williamson PR, Bennett JE, Robbins JB, Schneerson R. Vaccination for prevention of cryptococcosis. 2nd International Conference on Cryptococcus and Cryptococcosis, September 19-23, 1993, Milan, Italy. Abstract L22.
75. Mukherjee J, Scharff MD, Casadevall A. Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains. Infect Immun 1995; 63: 3353-3359.
76. Schneerson-Porat S, Sharar A, Aronson M. Formation of histiocyte rings in response to Cryptococcus neoformans infection. RES J Reticuloendothel Soc 1965; 2: 249-255.
77. Shahar A, Kletter Y, Aronson M. Granuloma formation in cryptococcosis. ISR J Med Sei 1969; 5: 1164-1172.
78. Griffin FM. Roles of macrophage Fc and C3b receptors in phagocytosis of immunologically coated Cryptococcus neoformans. Proc Natl Acad Sei USA 1980; 78: 3853-3857.
79. Mukherjee S, Feldmesser M, Casadevall A. J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. J Infect Dis 1996; 173: 1222-1231.
80. Mukherjee S, Lee SC, Casadevall A. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun 1995; 63: 573-579.
81. Spira G, Paizi M, Mazar S, Nussbaum G, Mukherjee S, Casadevall A. Generation of biologically active anti-Cryptococcus neoformans IgG, IgE and IgA isotype switch variant antibodies by acridine orange mutagenesis. Clin Exp Immunol 1996; 105: 436-442.
82. Zhong Z, Pirofski LA. Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies. Infect Immun 1996; 64: 3446-3450.
83. Vecchiarelli A, Retini C, Monari C, Casadevall A. Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T-cell proliferation. Infect Immun 1998; 66: 1244-1247.
84. Monari C, Kozel TR, Casadevall A, et al. B7 costimulatory ligand regulates development of the T-cell response to Cryptococcus neoformans. Immunology 1999; 98: 27-35.
85. Retini C, Casadevall A, Pietrella D, et al. Specific activated T cells regulate IL-12 production by human monocytes stimulated with Cryptococcus neoformans. J Immunol 1999; 162: 1618-1623.
86. Yuan RR, Casadevall A, Oh J, Scharff MD. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc Natl AcadSei USA 1997; 94:2483-2488.
87. Mody CH, Syme RM. Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans. Infect Immun 1993; 61: 464-469.
88. Retini C, Vecchiarelli A, Monari C, Bistoni F, Kozel TR. Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect Immun 1998; 66: 664-669.
89. Vecchiarelli A, Retini C, Pietrella D, et al. Down-regulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-l secretion from human monocytes. Infect Immun 1995; 63: 2919-2923.
90. Vecchiarelli A, Retini C, Monari C, et al. Purified capsular polysaccharide of Cryptococcus neoformans induces IL-10 secretion by human monocytes. Infect Immun 1996; 64: 2846-2849.
91. Vecchiarelli A, Retini C, Pietrella D, et al. T lymphocyte interaction by CD40/CD40 ligand facilitates a lymphoproliferative response and killing of Cryptococcus neoformans in vitro. Eur J Immunol 2000; 30: 1385-1393.
92. Pietrella D, Monari C, Retini C, Palazzetti B, Kozel TR, Vecchiarelli A. HIV type 1 envelope glycoprotein gp120 induces development of a T helper type 2 response to Cryptococcus neoformans. AIDS 1999; 13: 2197-2207.
93. Savoy AC, Lupan DM, Manalo PB, et al. Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis. Infect Immun 1997; 65: 1800-1807.
94. Lendvai N, Casadevall A. Monoclonal antibody-mediated toxicity in Cryptococcus neoformans infection: mechanism and relationship to antibody isotype. J Infect Dis 1999; 180: 791801.
95. Lendvai N, Qu X, Hsueh W, Casadevall A. Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans-infected mice. J Immunol 2000; 164:4367-4374.
96. Goldman DL, Lee SC, Mednick AJ, Montella L, Casadevall A. Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide. Infect Immun 2000; 68: 832-838.
97. Kozel TR. Opsonization and phagocytosis of Cryptococcus neoformans. Arch Med Res 1993; 24: 211-218.
98. Vecchiarelli A, Casadevall A. Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity. Res Immunol 1998; 149: 321-333.
99. Levitz SM, Nong SM, Seetoo KF, Harrison TS, Speizer RA, Simons ER. Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect Immun 1999; 67: 885-890.
100. Flesch IEA, Schwamberger G, Kaufman SHE. Fungicidal activity of IFN-gamma activated macrophages. J Immunol 1989; 142: 3219-3224.
101. Feldmesser M, Kress Y, Novikoff P, Casadevall A. Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect Immun 2000; 68: 4225-4237.
102. Meyaard L, Hovenkamp E, Otto SA, Miedema F. IL-12 induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune response. J Immunol 1996; 156: 2776-2782.
103. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998; 70: 83-243.
104. Decken K, Köhler G, Palmer-Lehmann K, et al. Interleukin-12 is essential for a protective Thl response in mice infected with Cryptococcus neoformans. Infect Immun 1998; 66: 4994-5000.
105. Huffnagle GB, Lipscomb MF. Cells and cytokines in pulmonary cryptococcosis. Res Immunol 1998; 149: 387-396.
106. Rincon M, Anguita J, Nakamura T, Fikrig E, Flavell RA. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med 1997; 185: 461-469.
107. Delfino D, Cianci L, Lupis E, et al. Interleukin-6 production by human monocytes stimulated with Cryptococcus neoformans components. Infect Immun 1997; 65: 2454-4556.
108. Delfino D, Cianci L, Migliardo M, et al. Tumor necrosis factor-inducing activities of Cryptococcus neoformans components. Infect Immun 1996; 64: 5199-5204.
109. Chaka W, Verheul AF, Vaishnav W, et al. Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells. Infect Immun 1997; 65: 272-278.
110. Retini C, Vecchiarelli A, Monari C, et al. Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect Immun 1996; 64: 2897-2903.
111. Lipovsky MM, Gekker G, Hu S, et al. Cryptococcal glucuronoxylomannan induces interleukin (IL)-8 production by human microglia but inhibits neutrophil migration toward IL-8. J Infect Dis 1998; 177: 260-263.
112. Walenkamp AM, Chaka WS, Verheul AF, et al. Cryptococcus neoformans and its cell wall components induce similar cytokine profiles in human peripheral blood mononuclear cells despite differences in structure. FEMS Immunol Med Microbiol 1999; 26: 309-318.
113. Chaka W, Verheul AF, Vaishnav VV, et al. Induction of TNF-alpha in human peripheral blood mononuclear cells by the mannoprotein of Cryptococcus neoformans involves human mannose binding protein. J Immunol 1997; 159: 2979-2985.
114. Pitzurra L, Cherniak R, Giammarioli M, et al. Early induction of interleukin-12 by human monocytes exposed to Cryptococcus neoformans mannoproteins. Infect Immun 2000; 68: 558-563.
115. Oosterwegel MA, Greenwald RJ, Mandelbrot BA, et al. CTLA4 and T cell activation. Curr Opin Immunol 1999; 11: 294-300.
116. Vecchiarelli A, Monari C, Retini C, et al. Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes. Eur J Immunol 1998; 28: 114-121.
117. Syme RM, Bruno TF, Kozel TR, Mody CH. The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody. Infect Immun 1999; 67: 4620-4627.
118. Bulmer GS, Sans MD. Cryptococcus neoformans. II. Phagocytosis by human leukocytes. J Bacterial 1967; 94: 1480-1483.
119. Diamond RD, Root RK, Bennett JE. Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro. J Infect Dis 1972; 125: 367-376.
120. Hidore MR, Murphy JW. Natural cellular resistance of beige mice against Cryptococcus neoformans. J Immunol 1986; 137: 3624-3631.
121. Monari C, Casadevall A, Retini C, et al. Antibody to capsular polysaccharide enhances the function of neutrophils from HIVinfected patients against Cryptococcus neoformans. AIDS 1999; 13: 653-660.
122. Alcovmire MS, Ghannoum MA, Ibrahim AS, et al. Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro. Anümicrob Agents Chemother 1993; 37: 2628-2632.
123. Monari C, Casadevall, Pietrella D, Bistoni F, Vecchiarelli A. Neutrophils from patients with advanced HIV infection have impaired complement receptor function and preserved Fey receptor function. J Infect Dis 1999; 180: 1542-1549.
124. Vecchiarelli A, Retini C, Casadevall A, et al. Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans. Infect Immun 1998; 66: 4324-4330.
125. Dong ZM, Murphy JW. Mobility of human neutrophiis in response to Cryptococcus neoformans cells, culture nitrate antigen, and individual component of the antigen. Infect Immun 1993; 61: 5067-5077.
126. Dong ZM, Murphy JW. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophiis. J Clin Invest 1996; 97: 689-698.
127. Dong ZM, Murphy JW. Cryptococcal polysaccharides bind to CD18 on human neutrophiis. Infect Immun 1997; 65: 557-563.
128. Huffnagle GB. Role of cytokines in T cell immunity to a pulmonary Cryptococcus neoformans infection. Biol Signals 1996; 5: 215-222.
129. Morel PA, Oriss TB. Crossregulation between Thl and Th2 cells. Crû Rev Immunol 1998; 18: 275-303.
130. Vecchiarelli A, Pietrella D, Dottorini M, et al. Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin Exp Immunol 1994; 98: 217-223.
131. Blackstock R. Cryptococcal capsular polysaccharide utilizes an antigen-presenting cell to induce a T-suppressor cell to secrete TsF. J Med Vet Mycol 1996; 34: 19-30.
132. Blackstock R, Casadevall A. Presentation of Cryptococcal capsular polysaccharide (GXM) on activated antigen-presenting cells inhibits the T-suppressor response under enhances delayed-type hypersensitivity and survival. Immunology 1997; 92: 334-339.
133. demons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Anlimicrob Agents Chemother 1994; 38: 460-464.
134. Dong ZM, Murphy JW. Intravascular Cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. Infect Immun 1995; 63: 770-778.
135. Luscinskas FW, Kiely JM, Ding H, et al. In vitro inhibitory effect of IL-8 and other chemoattractants on neutrophil-endothelial adhesive interactions. J Immunol 1992; 149: 21632171.
136. Murphy JW. Influence of Cryptococcal antigens on cell-mediated immunity. Rev Infect Dis 1988; 10 (Suppl. 2): S432-S435.
137. Murphy JW, Mosley RL, Cherniak R, et al. Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens. Infect Immun 1988; 56: 424-431.
138. Orendi JM, Verheul AF, De Vos NM, et al. Mannoproteins of Cryptococcus neoformans induce proliferative response in human peripheral blood mononuclear cells (PBMC) and enhance HIV-1 replication. Clin Exp Immunol 1997; 107: 293-299.
139. Pitzurra L, Vecchiarelli A, Peducci R, Cardinali A, Bistoni F. Identification of a 105 kilodalton Cryptococcus neoformans mannoprotein involved in human cell-mediated immune response. J Med Vet Mycol 1997; 35: 299-303.